These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. Washburn K; Speeg KV; Esterl R; Cigarroa F; Pollack M; Tourtellot C; Maxwell P; Halff G Transplantation; 2001 Nov; 72(10):1675-9. PubMed ID: 11726831 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial. Abramowicz D; Vanrenterghem Y; Squifflet JP; Kuypers D; Mourad M; Meurisse M; Wissing M Clin Transplant; 2005 Aug; 19(4):475-82. PubMed ID: 16008591 [TBL] [Abstract][Full Text] [Related]
26. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943 [TBL] [Abstract][Full Text] [Related]
27. Clinical Implication of Mycophenolic Acid Trough Concentration Monitoring in Kidney Transplant Patients on a Tacrolimus Triple Maintenance Regimen: A Single-Center Experience. Rhu J; Lee KW; Park H; Park JB; Kim SJ; Choi GS Ann Transplant; 2017 Nov; 22():707-718. PubMed ID: 29180612 [TBL] [Abstract][Full Text] [Related]
28. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Ekberg H; Bernasconi C; Tedesco-Silva H; Vítko S; Hugo C; Demirbas A; Acevedo RR; Grinyó J; Frei U; Vanrenterghem Y; Daloze P; Halloran P Am J Transplant; 2009 Aug; 9(8):1876-85. PubMed ID: 19563339 [TBL] [Abstract][Full Text] [Related]
29. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients. Bruce DS; Sollinger HW; Humar A; Sutherland DE; Light JA; Kaufman DB; Alloway RR; Lo A; Stratta RJ Transplantation; 2001 Nov; 72(10):1637-43. PubMed ID: 11726823 [TBL] [Abstract][Full Text] [Related]
30. Late evolution of kidney transplants in elderly donors and recipients receiving initial immunosuppressant treatment with daclizumab, mycophenolate mofetil, and delayed introduction of tacrolimus. González-Roncero FM; Gentil-Govantes MÁ; González-Molina M; Rivero M; Cantarell C; Alarcón A; Franco A; Sánchez-Plumed J; Lampreabe I; Lauzurica R; González E; Romero R; Ruiz-San Millán JC; Osuna A Nefrologia; 2012 Jul; 32(4):446-54. PubMed ID: 22806279 [TBL] [Abstract][Full Text] [Related]
31. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. Hirose R; Roberts JP; Quan D; Osorio RW; Freise C; Ascher NL; Stock PG Transplantation; 2000 Jan; 69(2):307-11. PubMed ID: 10670644 [TBL] [Abstract][Full Text] [Related]
32. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin. Libório AB; Mendoza TR; Esmeraldo RM; Oliveira ML; Paes FJ; Silva Junior GB; Daher EF Int Immunopharmacol; 2011 Nov; 11(11):1832-6. PubMed ID: 21835269 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Yoshida EM; Marotta PJ; Greig PD; Kneteman NM; Marleau D; Cantarovich M; Peltekian KM; Lilly LB; Scudamore CH; Bain VG; Wall WJ; Roy A; Balshaw RF; Barkun JS Liver Transpl; 2005 Sep; 11(9):1064-72. PubMed ID: 16123958 [TBL] [Abstract][Full Text] [Related]
34. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study. Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788 [TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. Pescovitz MD; Bumgardner G; Gaston RS; Kirkman RL; Light S; Patel IH; Nieforth K; Vincenti F Clin Transplant; 2003 Dec; 17(6):511-7. PubMed ID: 14756266 [TBL] [Abstract][Full Text] [Related]
36. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Thomas PG; Woodside KJ; Lappin JA; Vaidya S; Rajaraman S; Gugliuzza KK Transplantation; 2007 Jun; 83(11):1509-12. PubMed ID: 17565326 [TBL] [Abstract][Full Text] [Related]
37. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients. Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352 [TBL] [Abstract][Full Text] [Related]
38. Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation. Lo A; Stratta RJ; Alloway RR; Egidi MF; Shokouh-Amiri MH; Grewal HP; Gaber AO Transplant Proc; 2001; 33(1-2):1701-3. PubMed ID: 11267477 [No Abstract] [Full Text] [Related]